<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>new drug approval from DCI</title>
    <link>https://www.taxtmi.com/forum/issue?id=4756</link>
    <description>Under Schedule Y, clinical trials must follow Phase I-IV definitions and category-based review tracks; applications require chemistry, manufacturing and control data, preclinical studies, protocols, investigator brochures, informed consent, and ethical committee submission. After trial completion a new drug application using Form 44 with full preclinical and clinical information, foreign marketing status, labels and samples is filed for regulatory review, typically taking many months.</description>
    <language>en-us</language>
    <pubDate>Tue, 25 Sep 2012 18:17:40 +0530</pubDate>
    <lastBuildDate>Thu, 23 Jan 2025 15:57:53 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=319071" rel="self" type="application/rss+xml"/>
    <item>
      <title>new drug approval from DCI</title>
      <link>https://www.taxtmi.com/forum/issue?id=4756</link>
      <description>Under Schedule Y, clinical trials must follow Phase I-IV definitions and category-based review tracks; applications require chemistry, manufacturing and control data, preclinical studies, protocols, investigator brochures, informed consent, and ethical committee submission. After trial completion a new drug application using Form 44 with full preclinical and clinical information, foreign marketing status, labels and samples is filed for regulatory review, typically taking many months.</description>
      <category>Discussion-Forum</category>
      <law>Customs</law>
      <pubDate>Tue, 25 Sep 2012 18:17:40 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/forum/issue?id=4756</guid>
    </item>
  </channel>
</rss>